| Literature DB >> 28201972 |
Ivana Stojanovic1, Mirjana Dimitrijevic1, Marta Vives-Pi2, Maria Jose Mansilla2, Irma Pujol-Autonell2, Silvia Rodríguez-Fernandez2, Lenka Palova-Jelínkova3, David P Funda4, Alisa Gruden-Movsesijan5, Ljiljana Sofronic-Milosavljevic5, Catharien M U Hilkens6, Eva Martinez-Caceres2, Djordje Miljkovic7.
Abstract
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Cell-based tolerogenic therapy; multiple sclerosis; regulatory T cells; rheumatoid arthritis; tolerogenic dendritic cells; type 1 diabetes
Mesh:
Substances:
Year: 2017 PMID: 28201972 DOI: 10.2174/1381612823666170214120708
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116